Dashboard
Manage Tickers

NVCTNuvectis Pharma, Inc.

Nasdaq nuvectis.com


$ 6.65 $ 0.02 (0.3 %)    

Wednesday, 07-Aug-2024 15:57:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.72 $ -4.76 (-1.08 %)
DIA $ 387.79 $ -2.19 (-0.56 %)
SPY $ 518.50 $ -3.49 (-0.67 %)
TLT $ 95.87 $ -0.68 (-0.7 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 6.64
$ 6.98
$ 6.61 x 100
-- x --
$ 6.54 - $ 6.98
$ 5.85 - $ 15.50
30,063
na
112.22M
$ 0.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-nuvectis-pharma-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on Nuve...
08/06/2024 18:42:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price...

nuvectis-pharma-q2-eps-026-inline
Nuvectis Pharma Q2 EPS $(0.26), Inline
08/06/2024 13:44:12

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is ...

hc-wainwright--co-reiterates-buy-on-nuvectis-pharma-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on Nuve...
05/08/2024 19:03:40

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price...

nuvectis-pharma-q1-eps-025-beats-040-estimate
Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.4...
05/07/2024 12:11:58

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.4...

nuvectis-pharmas-nxp900-demonstrates-robust-activity-in-non-small-cell-lung-cancer-cell-lines
Nuvectis Pharma's NXP900 Demonstrates Robu...
04/08/2024 12:41:45

Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in...

nuvectis-pharma-announced-33-response-rate-and-100-disease-control-rate-observed-in-patients-evaluated-for-efficacy-from-the-nxp800-phase-1b-clinical-trial-in-platinum-resistant-arid1a-mutated-ovarian-cancer
Nuvectis Pharma Announced 33% Response Rat...
03/14/2024 13:47:15

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/14/2024 13:06:15

nuvectis-pharma-announces-preliminary-data-from-nxp800-phase-1b-clinical-trial-in-platinum-resistant-arid1a-mutated-ovarian-cancer
Nuvectis Pharma Announces Preliminary Data...
03/14/2024 13:02:14

 33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tum...

nuvectis-pharma-inc-reports-fiscal-year-2023-eps-143-vs-151-yoy
Nuvectis Pharma, Inc. Reports Fiscal Year ...
03/05/2024 13:21:39

NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
01/18/2024 17:31:14

nuvectis-pharma-inc-announces-a-collaboration-with-mayo-clinic-to-evaluate-nxp800-in-an-investigator-sponsored-clinical-trial-in-cholangiocarcinoma
Nuvectis Pharma, Inc. Announces A Collabor...
12/18/2023 13:06:57

Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial fo...

nuvectis-pharma-q3-eps-037-misses-034-estimate
Nuvectis Pharma Q3 EPS $(0.37) Misses $(0....
11/08/2023 13:10:51

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0...

recap-nuvectis-pharma-q3-earnings
Recap: Nuvectis Pharma Q3 Earnings
11/08/2023 13:10:06

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
10/17/2023 17:31:01

nuvectis-pharma-announces-upcoming-presentations-for-nxp800-and-nxp900
Nuvectis Pharma Announces Upcoming Present...
09/21/2023 12:01:20

hc-wainwright--co-reiterates-buy-on-nuvectis-pharma-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on Nuve...
09/15/2023 10:10:00

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price...

nuvectis-pharma-initiates-nxp900-phase-1a-clinical-trial
Nuvectis Pharma Initiates NXP900 Phase 1a ...
09/12/2023 12:02:14

 Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company ...

the-fda-has-granted-orphan-drug-designation-to-nuvectis-pharmas-nxp800-for-cholangiocarcinoma
The FDA Has Granted Orphan Drug Designatio...
08/17/2023 12:02:18

10-short-squeeze-stocks-to-watch-blue-apron-intuitive-machines-yellow-corp-getty-images-and-more
10 Short Squeeze Stocks To Watch: Blue Apr...
08/14/2023 14:49:47

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for th...

nuvectis-pharma-q2-eps-038-misses-029-estimate
Nuvectis Pharma Q2 EPS $(0.38) Misses $(0....
08/09/2023 12:33:12

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION